ArticleInternational journal of clinical and experimental pathology2015
Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Pooled it
- Integrative rank-based regression for multi-source high-dimensional data with multi-type responses.Journal of applied statistics · 2025Article
- Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma.Biomedicines · 2024Article
- Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus-related hepatocellular carcinoma.Cancer medicine · 2024Article
- Genetic predisposition to lung adenocarcinoma outcome is a feature already present in patients' noninvolved lung tissue.Cancer science · 2023Article
- A novel necroptosis-related gene index for predicting prognosis and a cold tumor immune microenvironment in stomach adenocarcinoma.Frontiers in immunology · 2022Review
- Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells.Oncology letters · 2021Article
- Article
- LINC00184 Promotes Ovarian Cancer Cells Proliferation and Cisplatin Resistance by Elevating CNTN1 Expression via Sponging miR-1305.OncoTargets and therapy · 2021Article
- Upregulated CNTN1 is associated with lymph node metastasis and poor prognosis of colorectal cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.Genes · 2020Review
- The Role of Contactin 1 in Cancers: What We Know So Far.Frontiers in oncology · 2020Review
- Article
- Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial-mesenchymal transition.Scientific reports · 2019Article
- Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies.Annals of clinical and translational neurology · 2018Article
- An individualized gene expression signature for prediction of lung adenocarcinoma metastases.Molecular oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contactin 1 (CNTN1) as a member of the immunoglobulin superfamily plays important role in the development of nervous system. Recent studies find that elevated CNTN1 can promote the metastasis of cancer. However, the expression and function of CNTN1 in thyroid cancer are still unknown. Here, we firstly find CNTN1 is a new gene which can be regulated by RET/PTC3 (Ret proto-oncogene and Ret-activating protein ELE1) rearrangement gene and the protein level of CNTN1 is increasing in thyroid cancer. Besides this change is positively associated with the TNM stage and tumor size. Moreover, we confirm that knockdown of CNTN1 significantly inhibits the tumor proliferation, invasiveness and represses the expression of cyclin D1 (CCND1). In conclusion, CNTN1 will be a potential diagnosis biomarker and therapy target for thyroid cancer.
Indexed as
Identifiers
26722434PMC4680379W2228673874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.